BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

28 related articles for article (PubMed ID: 15972368)

  • 1. Adverse drug event monitoring at the Food and Drug Administration.
    Ahmad SR
    J Gen Intern Med; 2003 Jan; 18(1):57-60. PubMed ID: 12534765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Report slams US FDA's drug safety reform efforts.
    Bristol N
    Lancet; 2007 Mar; 369(9567):1072. PubMed ID: 17405202
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA's sentinel network: a monumental task.
    Young D
    Am J Health Syst Pharm; 2007 Apr; 64(8):800-1. PubMed ID: 17420189
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA's monitoring of postmarketing studies probed.
    Young D
    Am J Health Syst Pharm; 2006 Aug; 63(16):1485-6. PubMed ID: 16896075
    [No Abstract]   [Full Text] [Related]  

  • 5. Monitoring drug product quality.
    Bolger G; Goetsch R; Reinstein P
    Am Pharm; 1992 Feb; NS32(2):47-9. PubMed ID: 1546630
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA's adverse-event surveillance needs improvement, advisers say.
    Traynor K
    Am J Health Syst Pharm; 2005 Jul; 62(13):1336, 1338, 1340. PubMed ID: 15972368
    [No Abstract]   [Full Text] [Related]  

  • 7. Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration.
    Brajovic S; Piazza-Hepp T; Swartz L; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):565-70; discussion 571-2. PubMed ID: 22359404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recognizing, reporting, and reducing adverse drug reactions.
    Brown SD; Landry FJ
    South Med J; 2001 Apr; 94(4):370-3. PubMed ID: 11332899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [FDA's new drug approval system].
    Ishii A
    Gan To Kagaku Ryoho; 1995 Aug; 22(9):1146-51. PubMed ID: 7661565
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices.
    Stergiopoulos S; Getz K
    Drug Saf; 2015 Aug; 38(8):687-92. PubMed ID: 26108298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting System.
    Chan-Tack KM; Struble KA; Birnkrant DB
    AIDS Patient Care STDS; 2008 Nov; 22(11):843-50. PubMed ID: 19025478
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.